CNBC
Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion
EconomyDaily Composite
Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.
C
Source
CNBC
Read full article at CNBC
Opens original article in a new tab
Advertisement


